Juniper Biomedical

Executive Summary

Juniper Biomedical is a preclinical-stage medical device company developing a precision neuromodulation platform for pelvic health disorders, such as urinary incontinence and pelvic pain. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company aims to address the limitations of current neuromodulation therapies by offering a minimally invasive, targeted implantable system that is more selective and energy-efficient. This approach could significantly improve patient outcomes and quality of life for millions suffering from these common conditions, which are often undertreated due to the invasiveness or side effects of existing options. The company is currently in the preclinical phase, focusing on device optimization and early feasibility studies. Juniper Biomedical's next major milestone is expected to be the submission of an Investigational Device Exemption (IDE) to the FDA, allowing the initiation of first-in-human clinical trials. Given the strong clinical need and the innovative nature of their technology, the company is well-positioned to attract further investment and strategic partnerships. Successful advancement through clinical trials could position Juniper as a leader in the pelvic neuromodulation space, with a potential market entry in the late 2020s.

Upcoming Catalysts (preview)

• Q3 2026IDE Submission to FDA70% success
• Q4 2026Series A Financing Close60% success
• Q1 2027First-in-Human Clinical Trial Initiation50% success